reference/20372784

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20372784

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	2468-2942
pageRange	100379-
publicationName	Cancer Treatment and Research Communications
startingPage	100379
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c053cec072f1fe69fb6fbfcc5c928aa6
bibliographicCitation	He H, Shi L, Meng D, Zhou H, Ma J, Wu Y, Wu Y, Gu Y, Xie W, Zhang J, Zhu Y. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner. Cancer Treatment and Research Communications. 2021;28():100379. doi: 10.1016/j.ctarc.2021.100379.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff4387222aaeba17682bbc692bad48af http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a1437af7f724e060f53d3677e50f5775 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6adf0a280905e3cf4053d4c2ff740bc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d23c022728cc2b86bb00df0d7c449ca5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c02ed2e02b84eb064c631e6099dad0c7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8eeecd9054102209e841865bc7fb75a2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cfe261c71e0427e4463d67b2ec090494 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f7c0c34468ac0a5db11ce11c52458bce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_776b94d840e8850bc847a0c2270c7cec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8dc433fba306eb265fe1ac23e283a8e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3864e235a00d5be7e57f27cf81f307d
date	2021
identifier	https://doi.org/10.1016/j.ctarc.2021.100379 https://pubmed.ncbi.nlm.nih.gov/33951555
isPartOf	https://portal.issn.org/resource/ISSN/2468-2942 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/45839
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner
discusses	http://id.nlm.nih.gov/mesh/M000675754 http://id.nlm.nih.gov/mesh/M0429936 http://id.nlm.nih.gov/mesh/M000600385 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0556121 http://id.nlm.nih.gov/mesh/M000678569
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000082082Q000627 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D061026Q000037 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D012878Q000188 http://id.nlm.nih.gov/mesh/D000067596Q000627 http://id.nlm.nih.gov/mesh/D008546Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D015496Q000276 http://id.nlm.nih.gov/mesh/D059016Q000187 http://id.nlm.nih.gov/mesh/D059016Q000276 http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D016246Q000187 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D007167 http://id.nlm.nih.gov/mesh/D000082082Q000494 http://id.nlm.nih.gov/mesh/D008546Q000276 http://id.nlm.nih.gov/mesh/D016246Q000276 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D015496Q000187 http://id.nlm.nih.gov/mesh/D018414Q000276 http://id.nlm.nih.gov/mesh/D061067Q000494 http://id.nlm.nih.gov/mesh/D004357 http://id.nlm.nih.gov/mesh/D000971Q000494 http://id.nlm.nih.gov/mesh/D012878Q000473 http://id.nlm.nih.gov/mesh/D012878Q000276 http://id.nlm.nih.gov/mesh/D008822 http://id.nlm.nih.gov/mesh/D000067596Q000494 http://id.nlm.nih.gov/mesh/D018414Q000187 http://id.nlm.nih.gov/mesh/D008546Q000473
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8448 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_68000b5f90a1d5b5b1a93dbb8aa92d3e http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f86d012b6bfa338654b1bd0723e283bf http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_29f84c0d894769b14b36c5f43f54153e http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Showing number of triples: 1 to 69 of 69.